Nicotinamide N-Methyltransferase Expression in Cervical Adenocarcinoma and Its Clinical Significance

  • Serra AkarEmail author
  • İsmail Harmankaya
  • Serdar Uğraş
  • Ersin Çintesun
  • Çetin Çelik
Original Article



Nicotinamide N-methyltransferase (NNMT) is a metabolic enzyme increasingly implicated in tumor progression and resistance to treatment. It is overexpressed in human cancers including glioblastoma, gastric, pancreatic, lung and colorectal cancers. The role of NNMT in cervical adenocarcinoma has not been studied thus far. We aimed to evaluate expression of NNMT in cervical adenocarcinoma and investigate its prognostic significance.


NNMT expression was assayed in 18 cases of cervical adenocarcinoma and 19 cases of benign cervical tissue. NNMT immunoreactivity was scored by multiplying staining intensity with percentage of immunoreactive cells.


The expression of NNMT was significantly higher in cervical adenocarcinoma than in benign tissue (p = 0.024). NNMT expression was significantly higher in patients with locally advanced than early cervical cancer (p = 0.031). NNMT expression was higher in patients with tumor size greater than 4 cm and in those with poorly differentiated tumors compared to patients with tumors of 4 cm or less and well-moderate differentiation, respectively (p = 0.044, p = 0.014).


Although on a preliminary level, this is the first study to detect an overexpression of NNMT in cervical adenocarcinoma and an increased expression associated with advanced stage, increased tumor size and poor differentiation. NNMT has been shown to carry prognostic and therapeutic importance in a variety of cancers, and it can be a potential treatment target in cervical adenocarcinomas.


Nicotinamide N-methyltransferase Cervical adenocarcinoma Stage Tumor size Tumor grade 


Author Contributions

S.A. contributed to idea development, data gathering and writing of manuscript. İ.H. contributed to data gathering and data analysis. S.U. contributed to data analysis and supervision. E.Ç. contributed to data analysis. Ç.Ç. contributed to supervision and the writing of manuscript.


This study was funded by the Scientific Research Project Endorsement (number 18401023).

Compliance with Ethical Standards

Conflict of interest

Authors declare no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors. This was a retrospective study of paraffin blocks and was approved by the Institutional Research Ethics Committee.


  1. 1.
    Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. Cancer Epidemiol Biomark Prev. 2017;26(4):444–57. Scholar
  2. 2.
    Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975–2004. Bethesda: National Cancer Institute; 2007.Google Scholar
  3. 3.
    Geraets D, Alemany L, Guimera N, et al. Detection of rare and possibly carcinogenic human papillomavirus genotypes as single infections in invasive cervical cancer. J Pathol. 2012;228:534–43.CrossRefGoogle Scholar
  4. 4.
    Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128:927.CrossRefGoogle Scholar
  5. 5.
    Katanyoo K, Sanguanrungsirikul S, Manusirivithaya S. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol Oncol. 2012;125:292.CrossRefGoogle Scholar
  6. 6.
    Munoz N, Bosch FX, de Sanjose S, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study G: epidemiologic classification of human papillomavirus types associated with cervical cancer. Engl. J. Med. 2003;348(6):518–27.CrossRefGoogle Scholar
  7. 7.
    Palanichamy K, Kanji S, Gordon N, et al. NNMT silencing activates tumor suppressor PP2A, inactivates oncogenic STKs, and inhibits tumor forming ability. Clin Cancer Res. 2017;23(9):2325–34. Scholar
  8. 8.
    Ulanovskaya OA, Zuhl AM, Cravatt BF. NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol. 2013;9(5):300–6. Scholar
  9. 9.
    Kanska J, Aspuria PP, Taylor-Harding B, et al. Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT. Oncotarget. 2017;8(16):26200–20. Scholar
  10. 10.
    Xu Y, Liu P, Zheng DH, et al. Expression profile and prognostic value of NNMT in patients with pancreatic cancer. Oncotarget. 2016;7(15):19975–81. Scholar
  11. 11.
    Chen C, Wang X, Huang X, et al. Nicotinamide N-methyltransferase: a potential biomarker for worse prognosis in gastric carcinoma. Am J Cancer Res. 2016;6(3):649–63.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Liang L, Zeng M, Pan H, Liu H, He Y. Nicotinamide N-methyltransferase promotes epithelial–mesenchymal transition in gastric cancer cells by activating transforming growth factor-β1 expression. Oncol Lett. 2018;15(4):4592–8. Scholar
  13. 13.
    Campagna R, Cecati M, Pozzi V, Fumarola S, Pompei V, Milanese G, Galosi AB, Sartini D, Emanuelli M. Involvement of transforming growth factor beta 1 in the transcriptional regulation of nicotinamide N-methyltransferase in clear cell renal cell carcinoma. Cell Mol Biol (Noisy-le-grand). 2018;64(7):51–5.CrossRefGoogle Scholar
  14. 14.
    Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009;105(2):107–8. Scholar
  15. 15.
    Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87.CrossRefGoogle Scholar
  16. 16.
    Xie X, Liu H, Wang Y, et al. Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway. Oncotarget. 2016;7(29):45837–48. Scholar
  17. 17.
    Sartini D, Seta R, Pozzi V, et al. Role of nicotinamide N-methyltransferase in non-small cell lung cancer: in vitro effect of shRNA-mediated gene silencing on tumourigenicity. Biol Chem. 2015;396(3):225–34. Scholar
  18. 18.
    Whatcott CJ, Diep CH, Jiang P, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res. 2015;21(15):3561–8.CrossRefGoogle Scholar
  19. 19.
    Baalbergen A, Ewing-Graham PC, Hop WC, Struijk P, Helmerhorst TJ. Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol. 2004;92:262–7.CrossRefGoogle Scholar
  20. 20.
    Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH, Do IG, Joh JW, Kim DS. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res. 2009;16(28):20. Scholar
  21. 21.
    Jung J, Kim LJY, Wang X, Wu Q, Sanvoranart T, Hubert CG, Prager BC, Wallace LC, Jin X, Mack SC, Rich JN. Nicotinamide metabolism regulates glioblastoma stem cell maintenance. JCI Insight. 2017;2(10):90019. Scholar

Copyright information

© Association of Gynecologic Oncologists of India 2019

Authors and Affiliations

  1. 1.Division of Gynecologic Oncology, Department of Obstetrics and GynecologySelcuk University Medical SchoolKonyaTurkey
  2. 2.Department of PathologySelcuk University Medical SchoolKonyaTurkey
  3. 3.Department of Obstetrics and GynecologySelcuk University Medical SchoolKonyaTurkey

Personalised recommendations